Details

Autor(en) / Beteiligte

• Balassa, K
• Andrikovics, H
• Remenyi, P
• Batai, A
• Bors, A
• Kiss, K P
• Szilvasi, A
• Rajczy, K
• Inotai, D
• Gopcsa, L
• Lengyel, L
• Barta, A
• Reti, M
• Tordai, A
• Masszi, T

Titel

The potential role of HLA-DRB111 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy

Ist Teil von

• Bone marrow transplantation (Basingstoke), 2015-10, Vol.50 (10), p.1321-1325

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Transplantation-associated thrombotic microangiopathy (TA-TMA) is a serious complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT) with high mortality rate. We retrospectively studied the frequency, clinical and genetic associations and prognostic effect of TA-TMA, in a total of 425 consecutive adult patients, who underwent allo-HSCT for a malignant haematological condition between 2007 and 2013 at our single centre. TA-TMA developed in 19% of the patients. Unrelated donor type (P<0.001), acute GvHD grades II-IV (P<0.001), myeloablative conditioning regimens (P=0.003), tacrolimus-based GvHD prophylaxis (P=0.003), CMV infection (P=0.003) and carriership for HLA-DRB1*11 (P=0.034) were associated with the development of TA-TMA. Survival was adversely affected by the presence of TA-TMA (P<0.001). Among patients with TA-TMA, the outcome of HLA-DRB1*11 carriers was significantly better compared with non-carriers (P=0.003). As a new finding, our observations suggest that the presence of HLA-DRB1*11 antigen contributes to the development of TA-TMA and affects the outcome.